Anti-OX40L/Anti-TNF bispecific nanobody

bispecific single-domain antibody targeting OX40L and TNF · Sanofi

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-OX40L/Anti-TNF bispecific nanobody, covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule [Phase 2]

See pricing